바카라사이트 카지노판 begins full-scale direct sales in Japan with launch of autoimmune disease treatment ‘Steqeyma’

[by Yu, Suin] 바카라사이트 카지노판 has initiated the commercialization of its autoimmune disease treatment, ‘Steqeyma (ustekinumab),’ in the Japanese market. The company has begun sales procedures and aims to implement a full-scale launch through its proprietary direct sales system, leveraging the distribution network it has established to date in order to actively penetrate the local market.

According to industry sources on July 10, 바카라사이트 카지노판 officially launched ‘Steqeyma (product name: Ustekinumab BS subcutaneous injection 45 mg syringe CT)’ in the Japanese market on July 8, approximately three months after receiving regulatory approval in March. The product is currently being sold through 바카라사이트 카지노판’s local subsidiary, ‘바카라사이트 카지노판 Healthcare Japan.’ Steqeyma is prescribed to patients with ‘plaque psoriasis’ and ‘psoriatic arthritis’ who have shown an inadequate response to existing treatments.

Steqeyma is a biosimilar (biopharmaceutical generic drug) of Stelara, an interleukin-12/23 (IL-12/23) inhibitor developed by Janssen, a subsidiary of the global pharmaceutical company Johnson & Johnson (J&J). The drug is indicated for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. With global 바카라사이트 카지노판 reaching around KRW 14 trillion (approximately USD 10.2 billion), Stelara was ranked among the 'Top 10' best-selling pharmaceuticals in the world in 2023.

Japan is experiencing a steady rise in demand for autoimmune disease treatments, driven by environmental changes and increasing life expectancy. Japan is the second-largest pharmaceutical market in Asia after China. In addition, the Japanese government is actively promoting biosimilar-friendly policies to alleviate the growing financial burden associated with rising pharmaceutical demand. Chairman Seo Jung-jin of 바카라사이트 카지노판 has reportedly identified Japan as a core strategic market and is known to make regular visits to the country to monitor local market developments.

Leveraging its prior experience in the ‘anticancer drug’ field, where it initially entered the Japanese market, 바카라사이트 카지노판 plans to accelerate the market stabilization of Steqeyma. The company also intends to further reinforce its local direct sales system. To date, 바카라사이트 카지노판 has pursued a dual-track distribution strategy, combining ‘corporate direct sales’ with ‘partnerships involving local firms (Nippon Kayaku).’ However, with the launch of Steqeyma, the company appears to be shifting toward a full-scale direct sales model. This approach offers advantages in maximizing sales effectiveness in terms of market response, strengthening brand credibility, and increasing overall profitability.

The effectiveness of 바카라사이트 카지노판’s locally established sales force is reflected in the growth trajectory of its previously launched anticancer biosimilar products. The company has implemented a sales strategy centered on in-person visits to medical institutions, carried out by its own marketing personnel and those of its partner companies, thereby increasing product awareness.

According to IQVIA and local market data, 바카라사이트 카지노판’s anticancer biosimilars, Herzuma (trastuzumab), indicated for breast and gastric cancers, and Vegzelma (bevacizumab), used for metastatic colorectal and breast cancers, are demonstrating strong performance in the Japanese oncology market. As of April this year, Herzuma holds an overwhelming 75% share of the Japanese market. Notably, it has maintained the No. 1 position in prescription volume for four consecutive years, following its initial surpassing of the original product’s market share in Q2 2021. Given that five trastuzumab formulations are currently available in Japan, Herzuma’s dominant market position underscores its market dominance over competing products.

Despite entering the market later than its competitors, Vegzelma has demonstrated impressive performance. Launched in Japan in January 2023, Vegzelma achieved a 29% market share as of April this year. In particular, the biosimilar is the most recent entrant among the six bevacizumab products currently available in the Japanese market. Its rapid growth is attributed to 바카라사이트 카지노판’s targeted marketing efforts and the product’s strong competitive profile, which have garnered significant local attention.

바카라사이트 카지노판 is also demonstrating strong prescription performance in the autoimmune disease sector. As a representative example, ‘Remsima (infliximab)’ ranked first among biosimilars in Japan, holding a 41% market share as of April this year. In addition, ‘Yuflyma (adalimumab)’ recorded a 12% market share during the same period, an increase of 1.5 times within just four months, rising from 8% to 12%.

In 2024, 바카라사이트 카지노판 Healthcare Japan reported sales of KRW 62.9 billion (approximately USD 45.8 million) and a net profit of KRW 1.1 billion. “Japan is a key pharmaceutical market in Asia, and we are concentrating our efforts on driving sales performance,” a 바카라사이트 카지노판 official said. “Our commitment extends beyond anticancer drugs to include autoimmune disease treatments, such as the newly launched Steqeyma.”